NASDAQ:CGC - Nasdaq - CA1380357048 - Common Stock - Currency: USD
1.61
-0.06 (-3.59%)
The current stock price of CGC is 1.61 USD. In the past month the price decreased by -27.8%. In the past year, price decreased by -52.08%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.16 | 828.87B | ||
JNJ | JOHNSON & JOHNSON | 15.98 | 384.45B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 26.17 | 371.73B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.65 | 231.22B | ||
MRK | MERCK & CO. INC. | 11.48 | 221.80B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.52 | 211.95B | ||
PFE | PFIZER INC | 8.33 | 146.78B | ||
SNY | SANOFI-ADR | 13.53 | 135.71B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.94 | 113.15B | ||
GSK | GSK PLC-SPON ADR | 7.88 | 75.42B | ||
ZTS | ZOETIS INC | 26.59 | 71.02B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.23 | 43.94B |
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 1,029 full-time employees. The company went IPO on 2010-06-04. The company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.
CANOPY GROWTH CORP
1 Hershey Dr
Smiths Falls ONTARIO K7A0A8 CA
CEO: David Klein
Employees: 1029
Company Website: https://www.canopygrowth.com/
Investor Relations: https://www.canopygrowth.com/
Phone: 18555589333
The current stock price of CGC is 1.61 USD. The price decreased by -3.59% in the last trading session.
The exchange symbol of CANOPY GROWTH CORP is CGC and it is listed on the Nasdaq exchange.
CGC stock is listed on the Nasdaq exchange.
17 analysts have analysed CGC and the average price target is 4.26 USD. This implies a price increase of 164.72% is expected in the next year compared to the current price of 1.61. Check the CANOPY GROWTH CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CANOPY GROWTH CORP (CGC) has a market capitalization of 279.14M USD. This makes CGC a Micro Cap stock.
CANOPY GROWTH CORP (CGC) currently has 1029 employees.
CANOPY GROWTH CORP (CGC) has a resistance level at 2.36. Check the full technical report for a detailed analysis of CGC support and resistance levels.
The Revenue of CANOPY GROWTH CORP (CGC) is expected to decline by -17.13% in the next year. Check the estimates tab for more information on the CGC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CGC does not pay a dividend.
CANOPY GROWTH CORP (CGC) will report earnings on 2025-05-30, after the market close.
CANOPY GROWTH CORP (CGC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.66).
The outstanding short interest for CANOPY GROWTH CORP (CGC) is 6.48% of its float. Check the ownership tab for more information on the CGC short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CGC. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CGC reported a non-GAAP Earnings per Share(EPS) of -3.66. The EPS increased by 74.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.34% | ||
ROE | -79.41% | ||
Debt/Equity | 0.79 |
ChartMill assigns a Buy % Consensus number of 47% to CGC. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 59.83% and a revenue growth -17.13% for CGC